Блог

Последни новини, научни статии и полезна информация за молекулярната онкологична диагностика и персонализираната терапия.

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
Биомаркери

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer...

16 март 2026 г.16 мин
Clinical potential and challenges of spatially profiling tumor-infiltrating lymphocytes in early-stage breast cancer
Биомаркери

Clinical potential and challenges of spatially profiling tumor-infiltrating lymphocytes in early-stage breast cancer

In this Perspective, David Page and colleagues discuss how spatially profiling immune-tumor cell interactions using multispectral immunofluorescence analyses holds promise as a biomarker to predict outcomes in early-stage breast cancer.

16 март 2026 г.8 мин
Inverse game theory characterizes frequency-dependent selection driven by karyotypic diversity in triple negative breast cancer
Биомаркери

Inverse game theory characterizes frequency-dependent selection driven by karyotypic diversity in triple negative breast cancer

Author summary Cancer evolves rapidly because tumor cells continuously change their genetic makeup, particularly through alterations in chromosome numbers via a process called chromosomal instability. This genetic variation allows multiple distinct cell popul…

16 март 2026 г.35 мин
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma
Биомаркери

Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma

A clinical trial testing whether monitoring ctDNA clearance during treatment for nasopharyngeal cancer could be used to inform decisions about an individual’s subsequent therapeutic programme shows promising results.

16 март 2026 г.2 мин
Next-generation programmable cell therapies for precision medicine
Биомаркери

Next-generation programmable cell therapies for precision medicine

In this Review, Teixeira et al. discuss emerging strategies for developing and improving engineered-cell therapies. They outline progress from ex vivo engineered autologous cells to in vivo reprogramming, advances in delivery systems and the remaining transla…

16 март 2026 г.2 мин
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Биомаркери

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease –

16 март 2026 г.5 мин

Страница 3 от 13 • Общо 75 статии